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The confinement ofmultiplemyeloma (MM) to the bonemarrowmicroenvironment requires an invasive bonemarrow
biopsy to monitor the malignant compartment. The existing clinical tools used to determine treatment response and
tumor relapse are limited in sensitivity mainly because they indirectly measure tumor burden inside the bone marrow
and fail to capture the patchy, multisite tumor infiltrates associated with MM. Microparticles (MPs) are 0.1- to 1.0-μm
membrane vesicles, which contain the cellular content of their originating cell. MPs are functional mediators
and convey prothrombotic, promalignant, proresistance, and proinflammatory messages, establishing intercellular
cross talk and bypassing the need for direct cell-cell contact in many pathologies. In this study, we analyzed plasma
cell–derivedMPs (CD138+) fromdeidentifiedMMpatients (n=64) and normal subjects (n=18) using flowcytometry.
Themorphology and size of theMPswere further analyzed using scanning electronmicroscopy. Our study shows the
proof of a systemic signature ofMPs inMMpatients.We observed that the levels ofMPswere significantly elevated in
MMcorresponding to the tumor burden.We provide the first evidence for the presence ofMPs in the peripheral blood
of MM patients with potential applications in personalized MM clinical monitoring.
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Recent advances in therapy for patients with multiple myeloma
(MM) using novel agents such as immunomodulatory drugs and
proteasome inhibitors have prolonged patient survival by an average
of 3 to 4 years [1]. Despite these advances, there is currently no means
to foresee impending relapse before the onset of clinical manifestations,
which results in the deterioration of the condition and requires a review
of the patient’s treatment regimen [2].
Relapse may be due to inherent genetic factors related to the
malignant clone or to the microenvironment. Monitoring for minimal
residual disease has involved flow cytometry or molecular methods of
patient blood samples and bone marrow aspirates to identify high-risk
groups [3]. However, there is a significant limitation in measuring the
duration of achieved remission and impending relapse before the clinical
manifestation in the current MM clinical setting. Consideration of the
impact and significance of membrane budding in MM has had little
attention. The physiological plasticity of the plasma membrane leads to
membrane budding, which results in the systemic release of submicron(0.1-1.0μm) fragments called microparticles (MPs). These vesicles are
shed in response to various stimuli during cellular activation and
apoptosis and are also involved in intercellular cross talk [4–6]. MPs are
detected systemically in healthy individuals; nevertheless, elevated levels
are indicative of cellular activation and are common in diseases
including diabetes, inflammation, vascular disease, and cancer [7–9].
Physiologically, MPs participate in cell signaling and also the exchange
of proteins and nucleic acids between distinct cell types. Their
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markers” of disease activity in poorly accessible tissues have been widely
documented [6,8,10,11]. Flow cytometric analysis is routinely used to
phenotypeMPs, as they display various cell surfacemarkers that define their
cellular origin [4,6]. MPs characteristically express phosphatidylserine (PS)
on their surface and are differentiated from other extracellular vesicles such
as exosomes (40-100 nm) and apoptotic bodies (N1 μm) by virtue of their
size and phenotype [6,12].
Platelet-derived MPs and their role in thromboembolic risk have
generated much interest and initiated specific studies in plasma cell
(PC) dyscrasias like MM [10]. The introduction of immunomodu-
latory drugs in MM therapy and their association with an increased
risk of venous thromboembolic episodes have initiated interest in
MPs in MM [10]. However, non–platelet-derived MPs (CD41a−) in
MM and their clinical significance have remained unstudied.
Among the various surface markers that are reflective of the
elaborate maturation and differentiation process in PCs, CD138 (a
transmembrane heparan sulfate proteoglycan) is expressed on the
surface of mature PCs [13]. CD138 acts as a classical co-receptor for
growth factors, angiogenic factors, and small signaling molecules like
chemokines [14–16]. CD138+/CD45− represents the phenotype of
mature PCs in bone marrow, and only CD138+ is considered to be an
exclusive marker for flow cytometric phenotyping of PCs [17,18].
The present study is designed to detect and enumerate the submicron
vesicles in the peripheral blood of MM patients (de novo and under
active treatment). As the peripheral blood of MM patients contains
platelet-derived MPs, we used CD41a which is a typical platelet
marker to exclude platelet-derived MPs from our population of
interest. Furthermore, we investigated the correlation between
number of CD138+ MPs and distinct clinical states. This study
describes for the first time the isolation and characterization of
CD138+/CD41a− MPs in the plasma of MM patients. We
demonstrate that the levels and phenotype of MPs are indicative of
the disease state and therapeutic outcome in MM patients. This
evidence suggests that MPs found in the blood could provide a novel
prognostic means to monitor the malignant cells in MM.
Materials and Methods
Antibodies and Reagents
Annexin V-V450 (BD Horizon, cat. no.560506), anti–CD138-APC
(clone MI15; cat. no. 347193), anti–CD41a-PE (clone HIP8; cat.
no. 555467), TruCount tubes (cat. no. 340334), and matched isotype
controls were purchased from BD Biosciences Australia/New Zealand.
Latex beads of diameter 0.3 μm (cat. no. LB3) and 1.1 μm (cat. no.
LB11) were from Sigma-Aldrich, Australia. Australian Microscopy and
Microanalysis Research Facility at the Australian center provided all
consumables for electron microscopy. Myeloma cell line OPM2 was
kindly provided by Royal Prince AlfredHospital Haematology, Sydney,
Australia, and was tested for mycoplasma at University of Technology
Sydney before use.
Study Design and Patient Selection Criteria
This study was approved by Sydney Local Health District Human
Research Ethics Committee (HREC) of Concord Repatriation General
Hospital (CRGH) (HREC/11/CRGH/223-CH62/6/2011-150),
Royal Prince Alfred Hospital HREC (SSA/12/RPAH/10), and
Human Research Ethics Committee at University of Technology
Sydney (2012-004R). The blood samples were collected from MMpatients and normal subjects (N18 years of age) after informed consent
at the CRGH and Royal Prince Alfred Hospital blood collection
centers. The subjects were de-identified (name and address) and were
assigned a code for accessing clinical information. This is a preliminary
study, and a predetermined sample size was not calculated because we
are analyzing all samples accessible following patient consent. Thus, we
are working with a fixed though unknown sample size. Normal subjects
were age-matched, noncancer patients with normal hematology who
presented at the hospital and were devoid of any cytotoxic treatment or
radiotherapy of any nature in the past 5 years. Pregnancy was also an
exclusion criterion. In total, 18 normal subjects and 64 MM subjects
were assessed, which included treatment-responsive [n = 26 and n = 18
for partial remission (PR) and complete remission (CR), respectively],
de novo (n = 8), and relapsed (n = 14) MM patients [19]. We had
access to the longitudinal samples for de novo cohort due to regular
clinical visits of this cohort for the front-line treatment, whereas theMP
data from remission, progressive disease (PD), and healthy cohorts
represent one point in time.
Isolation of Microparticles from MM Patient Peripheral Blood
Up to 4 ml of EDTA whole blood was centrifuged at 1500 × g for
20 minutes at room temperature (RT) to obtain platelet-poor plasma
and followed by 13,000 × g for 2 minutes at RT to obtain platelet-free
plasma (PFP) from the supernatant [20]. The PFP was divided into
200-μl aliquots, which were subjected to direct immunolabeling or
MP isolation by ultracentrifugation at 18,890 × g, 4°C for 30 minutes
[20]. The supernatant was removed, and the MP pellet was
immunolabeled for flow cytometry. Technical triplicates were
performed for each patient MP count. Biological replicates were
not feasible because of the small volume of sample from each patient.
Data Acquisition and Flow Cytometric Detection ofMicroparticles
Flow cytometric analyseswere conducted using anLSRII flow cytometer
and the CellQuest Pro analysis software (BD Biosciences, Australia/New
Zealand). Latex beads of 0.3 and 1.1μmdiameters were prepared and used
according to the manufacturer’s recommendation to define the MP gate.
Compared with MPs, latex beads typically have higher refractive indices
and, consequently, lower limits of size detection by flow cytometry [20,21].
As a result, the threshold in forward and side scatter was adjusted to avoid
background noise during acquisition. The predefinedMP gate was applied
to all samples during analysis. The performance of lasers was validated
before each experiment using Sphero Rainbow calibration particles (BD,
Australia/New Zealand; cat. no. 559123).
Surface Protein Phenotyping of Microparticles
Microparticles were isolated and validated as previously described by us
[6].Detection of the cell surface antigens, CD138,CD41a, andAnnexinV
was run in parallel with relevant isotype controls and unstained controls for
MP samples isolated from both MM patients and normal age-matched
healthy subjects. Compensation of fluorophores was established using the
setup feature in BD FACSDiva software. To detect and exclude
platelet-derived MPs during the analysis, the isolated MP pellet was dual
labeled using 5 μl of anti–CD138-APC and 20 μl of anti–CD41a-PE for
30 minutes at RT. MPs were pelleted at 18,890 × g, 4°C for 30 minutes
and resuspended in 200 μl of PBS for flow cytometric analysis.
Sample Storage Optimization
In assessing the effects of sample freezing on antigen detection, PFP
prepared from freshly collected blood was divided into 200-μl aliquots.
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hours and analyzed by surface protein phenotyping.
Quantitation of Systemic Microparticles
Isolated PC-derived MPs were resuspended in 200 μl of PBS and
added to BD TruCount tubes as per the manufacturer’s recommen-
dation for quantitation. The tube was vortexed gently before data
acquisition. The number of MPs per μl of plasma was calculated
using the manufacturer’s formula: N = [MP number of measured
beads] × [beads per tube/sample volume added]. The stop gate was set
at a fixed number of 2000 or 10000 of TruCount beads during the
data acquisition.
Microparticle Morphology
One percent polyethylenimine–coated Thermanox coverslips were
prepared, and the MP suspension (in PBS) was immobilized onto the
coated cover slips for 30 minutes. The coverslips were washed in
0.1 M PBS (pH 7.4) and fixed in primary fixative 2.5% (v/v)
glutaraldehyde in 0.1 M phosphate buffer for 30 minutes. Buffer
washes were performed before the addition of secondary fixative 1%
osmium tetroxide for 1 hour. The coverslips were washed 3 times for
5 minutes each with ultrapure water. A series of dehydration steps in
30% to 95% ethanol was performed for 5 minutes in each step,
followed by a final wash in ultrapure ethanol twice for 10 minutes.
Coverslips were left in hexamethyldisilazane for 2 minutes, following
which the hexamethyldisilazane was completely removed before
air-drying the sample overnight. The samples were mounted onto
silver specimen stubs with double-sided carbon tape, lined with silver
DAG, and coated with platinum. Scanning electron microscopy
(SEM) was performed using a Zeiss Ultra Plus FESEM (Carl Zeiss,
Oberkochen, Germany) at secondary electron at 10 kV. MP
morphology were visualized across all clinical states: de novo,
remission, and relapsed. OPM2 cell–derived MPs were used as
controls. MP size was analyzed using ImageJ software (U.S. National
Institutes of Health, Bethesda, MD). The experiment was performed
in technical duplicates for each patient sample.
Statistical Analysis
Mann-Whitney (U) test was conducted for the nonparametric data
using GraphPad Prism version 6.0 for Mac (GraphPad, La Jolla, CA).
The data are presented as the mean or mean ± SD and
Mann-Whitney constant U as stated. The results with a predictive
value of (****) P b .0001, (**) P b .01, and (*) P b .05 were
considered significant.
Results
Detection of PC-Derived Microparticles from PFP
MPs were isolated by differential high-speed centrifugation, as we
have previously described [6]. PFP was used as the starting material to
ensure that contamination by platelet-derived MPs in the final
preparation was minimized. MPs were validated by flow cytometry
for typical characteristics of size and phosphatidylserine exposure
(using Annexin V-V450) (Figure 1, A and B). The gating parameters
for the MP region (R3) were defined using 0.3-μm latex beads (R1:
the lowest possible limit on FS for BD LSRII) and 1.1-μm beads (R2:
represents the upper limit for MPs, Figure 1A).
As platelet-derived MPs comprise the major population systemi-
cally, our analysis was confined to CD41a− (platelet marker) MPs.
MPs arising from PCs were detected using anti–CD138-APC mAb(clone MI15). CD138 is an exclusive marker of PCs and allows for
the detection of MPs originating from PCs [17].
We observed a significantly greater number of MPs from patient
samples relative to healthy subjects. In the plasma of healthy volunteers,
we observed that 1.5% of total MPs were Annexin V+ CD138+
(Figure 1B, left panel) relative to 0.09% for isotype control (data not
shown). In contrast, we observed that 12. 8% of total MPs were Annexin
V+ CD138+ (Figure 1B, right panel) relative to 0.46% for isotype control
(data not shown). As PS expression is not an exclusive criterion forMPs, as
not all MPs expose PS, we consequently chose to identify MPs based on
their size and their phenotype.
Sample Storage Optimization
Freezing PFP before the MP isolation was shown to have
significant impact on the integrity of the CD138 marker on MPs.
Specifically, in the representative data, we observed that 24% of the
gated population detected CD138+ using fresh sample (Figure 2A)
compared with 5.63% for the same sample after freezing (Figure 2B).
Consequently, MP isolation was conducted using freshly isolated PFP
without freezing.
Total Microparticle Numbers Increase in MM
In considering the cohort data, we observed greater numbers of
total MPs in MM patients relative to healthy volunteers (Figure 3A).
The absolute number of MPs from MM patients was on average
seven-fold greater per μl relative to healthy volunteers (U = 30, P b
.0001). Consistent with this, we observed greater numbers of total
MPs for de novo patients (U = 71.50, P b .0001), patients in
remission (CR: U = 2, P b .0001; PR: U = 15, P b .0001), and
patients with PD (U = 9, P b .0001) relative to healthy volunteers
(Figure 3B). We observed no significant difference in total MP counts
across the different clinical states.CD138+ Microparticle Numbers Increase in MM
In considering the cohort data, we observed greater numbers of
CD138+ MPs in MM patients relative to healthy volunteers
(Figure 4A). The absolute number of CD138+ MPs fromMMpatients
was on average 3.45 fold greater per μl relative to healthy volunteers
(U = 632, P b .01). Consistent with this, we observed greater numbers
of CD138+ MPs for patients in CR/PR and with PD relative to healthy
volunteers. We observed no significant difference between healthy and
de novo patients, which we attribute to early stage of disease at diagnosis
for 75% of patients examined. We measured greater, albeit
insignificant, CD138+ MP numbers for patients with PD relative to
those in remission. MM stem cells (“side population”) are known to
contribute to MM relapse. These tumor-initiating cells are also
phenotypically CD138− and may impact MP counts for some patients
with PD [22,23]. CD138+ MP numbers were greater in patients in PR
(n = 26), in CR (n = 18), and with PD (n = 14) relative to healthy
volunteers (n = 18). P b .05 (*), P b .01 (**) (data not shown). We
observed significantly increased CD138+ MP counts in CR (U = 49,
P b .0022), PR (U = 25, P b .0231), and PD (U = 23, P b .0018)
relative to de novo patients (Figure 4B). Furthermore, we also identified
five patients who were in CR at the time of analysis who had greater
CD138+ MPs counts relative to the rest of the cohort (gray circles,
Figure 4B). These same patients were found to clinically relapse a few
weeks later, demonstrating the sensitivity and potential for CD138+
MP numbers to predict the transition between remission and PD in the
absence of clinically used markers of relapse in individual patients.
Figure 1. Detection of PC-derived MPs from PFP. Latex beads of known diameter (0.3 and 1.1 μm; Sigma-Aldrich) were used to define
the size gates. (A) R3 represents the MP region based on the lower (R1) and upper limit (R2) set by the beads. The predefined size gating
(R3) was applied to the patient’s MP scatter plot to identify the region of interest. The total number of acquired events when the stop gate
was set at 10,000 TruCount bead counts is shown on the right. (B) In the left scatter plot, MPs isolated from the PFP taken from a normal
healthy volunteer with only 1.5% MPs were Annexin V+ CD138+, whereas 12.8% of MPs isolated from MM patient were Annexin V+
CD138+ as shown on the right.
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in Individual Patients
We observed a significant prognostic potential for CD138+ MPs in
predicting “risk of relapse” and therapeutic response in individual
patients. We conducted a series of assessments whereby we profiled
CD138+ MPs from diagnosis throughout the course of therapy for
eight individual patients. Figure 5 summarizes the case of a
52-year-old female MM patient. CD138+ MP count fell in
accordance with response to treatment (Figure 5A). The patient’s
free kappa/lambda ratio also showed a decrease, in response to
therapy, consistent with a decline in tumor burden. However, soon
after, the patient developed plasmacytomas around the hip area
together with bone lesions in the spine, pelvis, and femur. We
observed a corresponding increase in CD138+ MPs, whereas we
observed no corresponding increase in paraprotein levels observed
during this same period (Figure 5B). The patient was then placed on a
thalidomide/dexamethasone maintenance regimen. This corre-Figure 2. Sample storage optimization. PFP was prepared, and
the sample was divided in two 200-μl aliquots. One sample was
immediately frozen at −80°C, whereas MPs were freshly isolated
from the other portion and subjected to immunolabeling. The frozen
sample was thawed on ice, followed by MP isolation and
fluorescence immunolabeling. (A) Twenty-four percent of MPs were
CD138+ for the fresh MP sample, whereas only 5.63% of MPs were
CD138+ when isolated from PFP post freezing/thawing (B).sponded with a drop in both CD138+ MP counts and IgG levels.
The patient underwent autologous stem cell transplant, CD138+ MP
counts increased, and IgG levels stabilized.
Morphology and Size of the Microparticles
SEM was used to visualize the morphology of MPs across different
clinical states. The morphology of MPs was compared with the
OPM2 myeloma cell line–derived MPs (Figure 6A, leftmost panel). In
de novo patients (Figure 6A, second panel from left) and patients in
remission (Figure 6A, third panel from left), MPs displayed a regular
spherical surface, whereas MPs isolated from relapsed patient
displayed an irregular surface with the presence of vacuoles and/or
craters (Figure 6A, rightmost panel). We observed no significant
difference in the size across distinct clinical response states with 0.75 ±
0.16 μm, 0.83 ± 0.53 μm, and 0.87 ± 0.44 μm for the de novo,
remission, and relapsed cases, respectively (Figure 6B).
Discussion
We report on the isolation and detection of non–platelet-derived
(CD41a−) CD138+ MPs in the blood of patients with MM. Our data
demonstrate that the total MP count is a predictor of the diseased
state in MM relative to healthy volunteers and is independent of theFigure 3. Total MP counts increase in MM. The total counts in MM
patients and healthy subjects were compared using themanufacturer’s
formula. (A) Total MP numbers were significantly greater in the MM
cohort relative to the healthy cohort. (B) TotalMP numberswere greater
in de novo (n = 8), PR (n = 26), CR (n = 18), and PD (n = 14) patients
relative to healthy subjects (n= 18) [P b .0001 (****)].
Figure 4. CD138+ MP increases in MM. The CD138+ MP counts
in MM patients and healthy subjects were compared using the
manufacturer’s formula. (A) CD138+ MP numbers were signifi-
cantly greater in the MM cohort relative to the healthy cohort. (B)
The absolute numbers of CD138+ MPs in the PD, CR, and PR
cohort were significantly increased compared with that of the de
novo cohort. Gray circles represent the patients that were found to
have PD in 3 to 4 weeks from sampling.
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MM patients relative to healthy volunteers. We showed that the
CD138+ MP count was significantly higher in MM patients during
the course of active therapy across the different clinical response
states. Also, we show that CD138+ MP count promises a sensitive
assessment of disease progression and therapeutic outcome in
individual MM patients. The substantial outcome of the study is
the prospective of a minimally invasive, effective systemic marker for
prognosis determination and prediction of therapeutic response during
the course of therapy.However, this is a pilot study, and further research
is required to confirm its usefulness in a clinical setting. For the same
reason, we were limited with only technical replicates of samples, and
biological replicates were not feasible at this stage.
Current response criteria assessment inMMrely on directmeasure of
disease burden via an invasive bone marrow biopsy, immunofixation,
serum protein electrophoresis, quantitation, measurement of free light
chain, and computed tomographic/magnetic resonance imaging scans
[24]. Nonetheless, all the abovemarkers have collectively failed to gaugeFigure 5. CD138+ microparticles in a 52-year-old patient during
patient at diagnosis and during the course of treatment. CD138+ MP
the course of clinical interventions. CD138+ MP counts fell follow
dexamethasone treatment (CyBorD). This corresponded to a drop in
with G-CSF. At this point, the patient developed bone lesions an
thalidomide/dexamethasone maintenance regimen. This correspond
patient underwent autologous stem cell transplant, CD138+MP counthe transition phase from orderly disease state to the progressive, and
thus novel systemic markers which can provide for this will aid in
improving the clinical management of MM.
Clinical monitoring of non-secretory MM was impeded until the
introduction of the light chain assays [25]. Free light chain assays
assess the free lambda, free kappa, and their ratio in the peripheral
blood as non-secretory MM lacks the classic paraprotein marker [19].
Nevertheless, clinical monitoring of non-secretory MM remains
limited as light chain assays have inadequacies including sample
dilution anomalies, calibration problems, and limits of detection,
which may result in erroneous inference of clinical significance [25].
As a stress response, the pliable plasma membrane undergoes lipid
bilayer remodeling, which in turn results in systemic shedding of the
MPs by most cell types [5,11]. MP levels are elevated in cancer and
inflammatory conditions and have a substantial pathophysiological
significance [6,11,26]. The surface molecules present on MPs identify
their cellular origin. MPs mediate both long-range and short-range
intercellular cross talk [4,5].
Microparticles are emerging as important “surrogate markers” of
many disease states as well as of physiologically less accessible tissues,
such as the endothelium [8,9]. Unresponsiveness to chemotherapeu-
tic regimens, resulting in relapse, is one of the characteristics of MM
[2]. Therefore, constant monitoring of the patient’s therapeutic
response is mandatory in the MM clinical setting [27]. However, the
neoplastic cells of MM are mostly restricted to the bone marrow until
advanced state; therefore, a systemic marker with personalized
prognostic capacity for determining treatment responsiveness in
MM is of significant clinical importance. Specifically, in the case of
non-secretory MM where the overproduction of the classical
paraprotein marker is absent, MP analysis will provide an important
supporting clinical diagnostic tool. Indeed, recently, elevated levels of
MPs were reported in late-stage MM than the early stage in a mouse
model study [28].
CD138 mediates PC to cell adhesion and is shed from the surface
of PCs to the microenvironment [29]. The molecule accumulates intreatment. MPs were isolated from the PFP of a 52-year-old MM
counts (A) were measured and profiled against IgG levels (B) during
ing the commencement of cyclophosphamide, bortezomib, and
IgG levels also. The patient then underwent stem cell mobilization
d plasmacytomas. Consequently, the patient was placed on a
ed with a drop in both CD138+ MP counts and IgG levels. The
ts increased, and IgG levels stabilized.
Figure 6. Morphology and size of the microparticles. SEM was used to visualize the morphology of MPs across different clinical
states. (A, leftmost panel) Electron micrographs of MPs isolated from myeloma cell line OPM2 (magnification, ×5.40 K) were used as a
control. (A, second and third from left panel, respectively) MPs isolated from OPM2 cells from a de novo patient sample (magnification,
×24.64 K) and from a patient in remission (magnification, ×19.40 K) had regular spherical surface. (A, rightmost panel) MPs isolated from
a relapsed MM patient had an irregular surface with the presence of vacuoles and/or craters (magnification, ×9.18 K). (B) No significant
differences in the size of MPs were observed across the different clinical states. Data are expressed as mean ± SD.
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proliferation and growth [30]. The loss of expression of CD138 from
PCs is correlated with a negative prognosis and is associated with
aggressive disease based on the in situ expression studies conducted on
bone marrow sections taken from MM patients [29,30]. Conse-
quently, a subpopulation of CD138− PCs in bone marrow has been
reported and is identified as immature compared with CD138+ [31].
According to the literature, CD138− PCs were found to be in the
S phase and therefore possess higher proliferation potential [31]. We
measured greater, albeit insignificant, CD138+ MP numbers for
patients with PD relative to those in remission. MM initiating cells
(“side population”) are known to contribute to MM relapse, are
phenotypically CD138−, and may be underestimating MP counts
(derived from CD138− PCs) for patients with PD [22,23]. The
transmembrane co-receptor CD138 is versatile as it can be cleaved off
from PC surface to bone marrow and transform to soluble effector
molecule, competing with the same ligands. However, CD138
enrichment and packaging into MPs during membrane remodeling as
a response to bioactive molecules could be one alternate pathway
orchestrated in MM pathogenesis and progression.
We have previously reported MPs as “submicron messengers” for
the “non-genetic” transfer of drug resistance in lymphoblastic
leukemic and breast cancer cell lines [6]. Furthermore, we have
established that MPs selectively package cargo, which in turn
contributes to the spread and acquisition of deleterious trait
dominance in cancer [32–35]. This study adds to this body of
research and provides support for the use of MPs as a novel prognostic
for the personalized therapeutic management of MM. We have also
shown that CD138+ MP counts can predict the transition between
remission and PD in the absence of clinically used markers of relapse
in individual patients before clinical manifestations. We did not
observe a significant difference in the CD138+ MPs between de novo
MM patient cohort and healthy volunteers that we attribute to theearly stage of disease at diagnosis for 75% of patients examined. We
also note that only eight de novo patients were sampled in this
analysis. The study was designed to acquire any MM sample available
to us at the given point of time. Therefore, we could only recruit a
limited number of patients before the start of chemotherapy. The
total numbers of MPs were higher in MM patients irrespective of the
clinical states. We observed that CD138+ MP count shows significant
reduction in a positive therapeutic response in individual patients as
shown in the representative case of a 52-year-old MM patient in this
study. We observed reduction in CD138+ MP count as a response to
therapy from baseline and an increase in CD138+ MP before the
clinical manifestation of PD.
The scanning electron micrographs of MPs isolated from patients
with MM (de novo, remission, and relapsed) and the OPM2 cell line
showed a spherical morphology with a mean size of 0.1 to 1 μm. In
contrast, MPs isolated from a relapsed patient mostly displayed an
irregular morphology with the presence of vacuoles or craters. The
reason for this is currently being investigated; however, it is known
that in a late-stage subset of MM, PCs lose their characteristic markers
harboring less differentiated B cell markers on their surface, and the
subset is known as PC leukemia [36]. It is interesting to note that our
earlier work has shown that MPs isolated from leukemia cells also
display an irregular surface [34] similar to the systemic MP from the
relapsed MM patient which may be consistent with this phenotype.
By virtue of our isolation technique, the vesicle fraction is consistent,
and their average size is around 0.7 μm, which exceeds the size of the
exosome population as supported by our SEM data. Other
contaminants like immune complexes or protein aggregates
(b80 nm) were also ruled out from our homogeneous vesicle fraction
by virtue of their size [34,37]. The conserved transmembrane
structure of CD138 maintains the morphology and cytoskeletal
organization of numerous cell types [38]. As described, cleaving of the
heparan sulfate–bearing ectodomain of CD138 from PC and
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reported in MM. High levels of CD138 in the serum of MM patients
have been described as a deleterious prognosis in MM [29]. Soluble
effector molecules act as a potential reservoir for the dissemination of
cancer progression, invasion, and metastasis in MM, influencing
morphology and cytoskeletal organization of PCs along with the
cell-extracellular matrix interactions. [30]. Thus, the loss of ectodomain
fromPC surface to bonemarrowmicroenvironment in progressiveMM
may affect the enrichment of CD138 intoMPs derived from them.This
might also explain the change of the morphology of PC-derived MPs
observed in our SEM images of relapsed patient.
In conclusion, we have demonstrated that there are significantly
elevated levels of total systemic MPs and, specifically, CD138+ MPs
in MM patient peripheral blood compared with healthy volunteers.
We propose a new clinical tool, which may support the existing
clinical assessment. Further studies will involve thorough correlative
studies to compare this methodology with existing clinical tools in the
context of disease management. To the best of our knowledge, this is
the first report on the isolation of non–platelet-derived MPs from
MM patients and the identification of circulating CD138+ MPs in
patients across all MM clinical states. This clinical study provides
support for a potential systemic and noninvasive prognostic
biomarker of MM. This novel noninvasive clinical test supports the
existing clinical tools, aiding to monitor transition between the
controlled and advanced disease state in MM. The future studies will
be focused into the clonal, resistance markers on MPs in MM and
their role in treatment failure in tumor cells in the bone marrow
during the course of MM chemotherapy. This is significant because
such tests are currently lacking. There is also currently no cure for
MM, and the unbiased survey of MPs we describe has the potential to
identify novel targets beyond prognostication into treatment.
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